The cost-benefit ratio of tetravalent rhesus rotavirus vaccine (RRV-TV) in Finland for prevention of rotavirus gastroenteritis was assessed in a randomized, double-blind, placebo-controlled trial.
Costs related to vaccination, side effects, and gastroenteritis were identified.
Children received RRV-TV (n=1,191) or placebo (n=1,207) at 2,3, and 5 months of age with other infant vaccinations.
Prospective follow-up averaged 1.0 years per child.
An intention-to-treat analysis was performed from the perspective of society.
Nine cases of severe rotavirus gastroenteritis occurred in the RRV-TV group, versus 100 in the placebo group (P<. 0001) ; mean cost per vaccinated child was 4 Finnish marks (FIM) in the RRV-TV group, versus 203 FIM in the placebo group.
Side effects with related costs occurred after 11% and 7% of doses in the RRV-TV group and placebo group, respectively (P<. 001) ; mean cost per child was 89 FIM vs. 75 FIM.
The break-even cost (i.e., net benefit, excluding cost of vaccine) of RRV-TV in prevention of severe rotavirus gastroenteritis was 109 FIM (U.S. $19.60) per child.
Mots-clés Pascal : Rotavirus, Reoviridae, Virus, Gastroentérite, Immunoprophylaxie, Vaccin associé, Vaccination, Finlande, Europe, Prévention, Analyse avantage coût, Efficacité, Toxicité, Effet secondaire, Enfant, Homme, Virose, Infection, Economie santé, Appareil digestif pathologie, Estomac pathologie, Intestin pathologie
Mots-clés Pascal anglais : Rotavirus, Reoviridae, Virus, Gastroenteritis, Immunoprophylaxis, Mixed vaccine, Vaccination, Finland, Europe, Prevention, Cost benefit analysis, Efficiency, Toxicity, Secondary effect, Child, Human, Viral disease, Infection, Health economy, Digestive diseases, Gastric disease, Intestinal disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0400987
Code Inist : 002B05C02F. Création : 25/01/1999.